ERBB2 and breast cancer: In addition, combining MM-111 with other HER2-targeted agents (trastuzumab and/or lapatinib) and chemotherapy (such as paclitaxel) synergistically inhibit tumor cell growth and prevent the development of HER3-driven drug resistance in gastric and breast cancer cells and xenografts (113–115).